DUSP12: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: DUSP12

NCBI ID: G11266

DUSP12

DUSP12: A Potential Drug Target Or Biomarker for Various Diseases

DUSP12 (DUS12_HUMAN), a protein that belongs to the DUSP family, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression pattern make it an attractive target for researchers to study and develop new therapeutic approaches.

The DUSP family is a group of transmembrane proteins that play a crucial role in intracellular signaling. The DUSP12 protein is a member of this family and is expressed in various tissues and organs in the human body. It is involved in several cellular processes, including cell signaling, cell adhesion, and intracellular signaling pathways.

One of the key features of DUSP12 is its ability to interact with various signaling molecules, including tyrosine kinases, G-protein-coupled receptors, and nuclear factor-kappa-B (NF-kappa-B). These interactions allow DUSP12 to regulate cellular processes and signaling pathways that are important for various biological processes, including cell growth, differentiation, and inflammation.

DUSP12 has been shown to play a role in several diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, DUSP12 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have also shown that DUSP12 is involved in the regulation of pain signaling pathways and that it may play a role in the development of chronic pain.

In addition to its potential involvement in disease, DUSP12 has also been shown to be a promising biomarker for several diseases. For example, DUSP12 has been shown to be involved in the regulation of inflammation and has been used as a biomarker for various inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

DUSP12 has also been shown to have potential therapeutic applications. For example, studies have shown that inhibiting DUSP12 activity can protect against neurodegenerative diseases and that it may be a useful target for drug development in these conditions. Additionally, DUSP12 has been shown to be involved in the regulation of cell signaling pathways and has been potential target for small molecules and antibodies that can modulate its activity.

In conclusion, DUSP12 is a protein that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression pattern make it an attractive target for researchers to study and develop new therapeutic approaches. Further research is needed to fully understand the role of DUSP12 in these diseases and to explore its potential as a therapeutic target.

Protein Name: Dual Specificity Phosphatase 12

Functions: Dual specificity phosphatase; can dephosphorylate both phosphotyrosine and phosphoserine or phosphothreonine residues. Can dephosphorylate glucokinase (in vitro) (By similarity). Has phosphatase activity with the synthetic substrate 6,8-difluoro-4-methylumbelliferyl phosphate and other in vitro substrates (PubMed:10446167, PubMed:24531476)

The "DUSP12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DUSP12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets